A Phase I Safety Study of NVG-291 in Healthy Adults
Status:
Recruiting
Trial end date:
2022-05-18
Target enrollment:
Participant gender:
Summary
This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded),
placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to
evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily
in healthy female participants. The trial is split into two parts, starting with Part 1 (SAD)
and then Part 2 (MAD). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Part
2 (MAD), participants receive 1 dose every day for 14 days.